Tenax Therapeutics’ (TENX) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Tenax Therapeutics (NASDAQ:TENX) in a report published on Monday morning,RTT News reports.

Separately, Leerink Partners set a $20.00 price target on shares of Tenax Therapeutics in a research report on Monday. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tenax Therapeutics Stock Up 3.4 %

NASDAQ:TENX opened at $6.40 on Monday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The company has a 50-day moving average of $6.44 and a 200 day moving average of $5.21.

Hedge Funds Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new position in Tenax Therapeutics in the 4th quarter worth approximately $1,026,000. Vestal Point Capital LP acquired a new position in Tenax Therapeutics in the 3rd quarter worth approximately $288,000. Stonepine Capital Management LLC acquired a new position in Tenax Therapeutics in the 3rd quarter worth approximately $173,000. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics in the 3rd quarter worth approximately $101,000. Finally, Millennium Management LLC acquired a new position in Tenax Therapeutics in the 4th quarter worth approximately $166,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.